259 related articles for article (PubMed ID: 11790297)
21. Endothelin receptor antagonists in the treatment of prostate cancer.
Lassiter LK; Carducci MA
Semin Oncol; 2003 Oct; 30(5):678-88. PubMed ID: 14571415
[TBL] [Abstract][Full Text] [Related]
22. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function.
Yamauchi-Kohno R; Miyauchi T; Hoshino T; Kobayashi T; Aihara H; Sakai S; Yabana H; Goto K; Sugishita Y; Murata S
Circulation; 1999 Apr; 99(16):2171-6. PubMed ID: 10217659
[TBL] [Abstract][Full Text] [Related]
23. ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats.
Oie E; Bjønerheim R; Grogaard HK; Kongshaug H; Smiseth OA; Attramadal H
Am J Physiol; 1998 Sep; 275(3):H868-77. PubMed ID: 9724291
[TBL] [Abstract][Full Text] [Related]
24. Endothelin and endothelin antagonists in hypertension.
Schiffrin EL
J Hypertens; 1998 Dec; 16(12 Pt 2):1891-5. PubMed ID: 9886874
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience with endothelin receptor antagonists in chronic heart failure.
Seed A; Love MP; McMurray JJ
Heart Fail Rev; 2001 Dec; 6(4):317-23. PubMed ID: 11447306
[TBL] [Abstract][Full Text] [Related]
26. Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.
Choussat R; Hittinger L; Barbe F; Maistre G; Carayon A; Crozatier B; Su J
Cardiovasc Res; 1998 Sep; 39(3):580-8. PubMed ID: 9861300
[TBL] [Abstract][Full Text] [Related]
27. Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders.
Goddard J; Webb DJ
Drugs R D; 1999 Jul; 2(1):1-12. PubMed ID: 10560541
[TBL] [Abstract][Full Text] [Related]
28. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats.
Sakai S; Miyauchi T; Sakurai T; Yamaguchi I; Kobayashi M; Goto K; Sugishita Y
J Am Coll Cardiol; 1996 Nov; 28(6):1580-8. PubMed ID: 8917275
[TBL] [Abstract][Full Text] [Related]
29. Will endothelin receptor antagonists have a role in heart failure?
Spieker LE; Lüscher TF
Med Clin North Am; 2003 Mar; 87(2):459-74. PubMed ID: 12693734
[TBL] [Abstract][Full Text] [Related]
30. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure.
Shimoyama H; Sabbah HN; Borzak S; Tanimura M; Shevlyagin S; Scicli G; Goldstein S
Circulation; 1996 Aug; 94(4):779-84. PubMed ID: 8772702
[TBL] [Abstract][Full Text] [Related]
31. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
Rondelet B; Kerbaul F; Motte S; van Beneden R; Remmelink M; Brimioulle S; McEntee K; Wauthy P; Salmon I; Ketelslegers JM; Naeije R
Circulation; 2003 Mar; 107(9):1329-35. PubMed ID: 12628956
[TBL] [Abstract][Full Text] [Related]
32. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators.
Spieker LE; Mitrovic V; Noll G; Pacher R; Schulze MR; Muntwyler J; Schalcher C; Kiowski W; Lüscher TF
J Am Coll Cardiol; 2000 Jun; 35(7):1745-52. PubMed ID: 10841220
[TBL] [Abstract][Full Text] [Related]
33. Bosentan: a dual endothelin receptor antagonist.
Rubin LJ; Roux S
Expert Opin Investig Drugs; 2002 Jul; 11(7):991-1002. PubMed ID: 12084009
[TBL] [Abstract][Full Text] [Related]
34. Endothelin antagonism with bosentan: current status and future perspectives.
Ono K; Matsumori A
Cardiovasc Drug Rev; 2002; 20(1):1-18. PubMed ID: 12070530
[TBL] [Abstract][Full Text] [Related]
35. Role of endothelin-1 in myocardial failure.
Sam F; Colucci WS
Proc Assoc Am Physicians; 1999; 111(5):417-22. PubMed ID: 10519162
[TBL] [Abstract][Full Text] [Related]
36. Is there a role for endothelin in the natural history of heart failure?
Cohn JN
Circulation; 1996 Aug; 94(4):604-6. PubMed ID: 8772676
[No Abstract] [Full Text] [Related]
37. Possible therapeutic role of endothelin antagonists in cardiovascular disease.
Ram CV
Am J Ther; 2003; 10(6):396-400. PubMed ID: 14624276
[TBL] [Abstract][Full Text] [Related]
38. Endothelin antagonism with bosentan: a review of potential applications.
Roux S; Breu V; Ertel SI; Clozel M
J Mol Med (Berl); 1999 Apr; 77(4):364-76. PubMed ID: 10353441
[TBL] [Abstract][Full Text] [Related]
39. Endothelin receptor antagonists: current status and perspectives.
Clozel M
J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S65-68. PubMed ID: 10976785
[TBL] [Abstract][Full Text] [Related]
40. Endothelins: pathophysiology and treatment implications in chronic heart failure.
Teerlink JR
Curr Heart Fail Rep; 2005 Dec; 2(4):191-7. PubMed ID: 16332312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
